Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ebola Crisis Causes Drug Claim Symptoms In Products Marketed As Supplements

This article was originally published in The Pink Sheet Daily

Executive Summary

FTC joins FDA in one of the three warning letters to firms claiming their products can either prevent or treat Ebola.

You may also be interested in...



FDA Litigates To Wash Off Sanitizer Ebola Claim, Warns On Colloidal Silver Benefits

A complaint filed in federal court in California seeks an order to block Innovative BioDefense from distributing Zylast antiseptic hand sanitizer products that, due to its claims, are unapproved new drugs under FDA regulations. A warning letter to Silver Armor states that drug claims render its Silver Ramon and Natural Health brand products, which contain colloidal silver, unapproved new drugs and that the is noncompliant with supplement GMP regulations.

Flu Ushers In Risky Claims Season

Supplement firms are safest avoiding any mention of the flu, and trade groups see flu claims as a red flag for other problems. But flu season perennially brings in claims that skirt – or cross – the line, where they could draw fire from FDA.

FTC Stakes New Territory, Joins FDA In Warning On H1N1 Claims

A warning letter sent jointly by FDA and the Federal Trade Commission takes a double-pronged approach toward cracking down on a supplement marketer's claims regarding the H1N1 flu virus

Topics

UsernamePublicRestriction

Register

PS076526

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel